For successful clinical tumor immunotherapy outcomes, strong immune responses against tumor antigens must be generated. Cell-based vaccines compromise one strategy with which to induce appropriate strong immune responses. Previously, we established a natural killer T-cell (NKT) ligand-loaded, adenoviral vector-transduced B-cell-based anticancer cellular vaccine. To enhance tumor antigen delivery to B cells, we established a modified adenoviral vector (Ad-k35) that encoded a truncated form of the breast cancer antigen Her2/neu (Ad-k35HM) in which fiber structure was substituted with adenovirus serotype 35. We observed increased tumor antigen expression with Ad-k35HM in both human and murine B cells. In addition, an Ad-k35HM-transduced B-cell vaccine elicited strong antigen-specific cellular and humoral immune responses that were further enhanced with the additional loading of soluble NKT ligand KBC009. An Ad-k35HM-transduced, KBC009-loaded B-cell vaccine efficiently suppressed the in vivo growth of established tumors in a mouse model. Moreover, the vaccine elicited human leukocyte antigen (HLA)-A2 epitope-specific cytotoxic T-cell responses in B6.Cg (CB)-Tg (HLA-A/H2-D) 2Enge/Jat mice. These findings indicated that the Ad-k35 could be appropriate for the preclinical and clinical development of B-cell-based anticancer immunotherapies. 
INTRODUCTION
Recently, cancer immunotherapies have been developed to overcome the difficulties associated with chemotherapy, radiotherapy and surgery, which are the most well-known cancer treatment strategies. 1 To this end, dendritic cell-based vaccines were developed to effectively induce robust immune responses against tumor antigens.
2-5 However, there is a need for more efficiently obtained alternative sources of cellular vaccines. In several previous studies, B cells were suggested as a new source of antigen-presenting cells (APCs) for cellular vaccines because of their abundance in the blood and their easy preparation. [6] [7] [8] [9] We previously showed that B cells loaded with natural killer T-cell (NKT) ligand-loaded B cells into which antigen was introduced by epitope peptide loading or adenoviral vector transduction, could induce strong and long lasting antigen-specific immune responses with the help from activated NKT cells. From these studies, we proposed that if supplemented with NKT ligands, B-cell-based vaccines could take the place of the dendritic cell-based vaccines. 6, 7, 10 Tumor antigen delivery to B cells is another important issue in the induction of strong antitumor immune responses. Adenoviral vector-mediated antigen delivery has been suggested as a useful strategy because a large gene that encodes the antigen of interest can be transferred to the APC, and the adenoviral construct might also act as an adjuvant. 11 Adenovirus serotype 5 (Ad) is a widely used adenoviral vector; [12] [13] [14] [15] [16] [17] [18] however, its usage was limited because of the lack of coxsackievirus and adenovirus receptor on APCs, including B cells. To overcome this, we previously reported the combined use of an adenoviral vector and an adapter molecule, CFm40L, to enhance adenoviral gene delivery to B cells. 19 In addition, adenovirus serotype 35 (Ad35) was recently suggested as alternative adenoviral vector for antigen gene delivery. [20] [21] [22] [23] The fiber knob of Ad35 is known to bind the CD46 molecule, which is widely expressed on human leukocytes, for cellular entrance, and this might enhance the adenoviral vector infectivity. 18, [24] [25] [26] Furthermore, there have been various challenges involved in the enhancement or specific targeting of adenoviral gene transduction with modified adenoviral vectors. 17, [27] [28] [29] [30] Adenovirus type 5, substituted with type 35's fiber knob (Ad-k35), is a vector that was shown to increased infectivity in human cells in either CD46-dependent or CD46-independent mechanisms. 31 In this study, we established an advanced B-cell-based vaccine by enhancing antigen gene delivery to B cells with the modified adenoviral vector Ad-k35 and additional loading with the NKT ligand KBC009. 32 With Ad-k35HM, we observed increased tumor antigen expression on both human and murine B cells. Furthermore, an Ad-k35HM-transduced B-cell-based vaccine elicited strong antigen-specific cellular and humoral immune responses, and these responses were further enhanced with additional KBC009 loading (B/Ad-k35HM/KBC009). Therefore, B/Ad-k35HM/KBC009 efficiently suppressed the in vivo growth of established tumors in a mouse model. Moreover, the vaccine elicited human leukocyte antigen (HLA)-A2 epitope-specific cytotoxic T-cell responses in HLA-A2 Tg mice. These findings suggest that the combined use of an NKT ligand and the 1 modified adenoviral vector Ad-k35 could be appropriate for the preclinical and clinical development of B-cell-based anticancer immunotherapies.
RESULTS

Enhanced transduction effect of the modified adenoviral vector, Ad-k35
To enhance the antigenic gene transfer, we established a green fluorescent protein (GFP)-expressing adenovirus in which the serotype 5 fiber knob was substituted with the fiber knob from type 35 (Ad-k35), thus generating Ad-k35GFP. To examine the transduction efficiency, we infected human dermal fibroblast cells with GFP-expressing type 5 adenovirus (AdGFP) or Ad-k35GFP, and identified GFP-expressing cells by fluorescence microscopy. More GFP-expressing human dermal fibroblast cells were detected in the Ad-k35GFP groups than in the AdGFP groups, (Figure 1a ). Next, we tested whether Ad-k35GFP also transduced the GFP gene more efficiently into human B cells. Human B cells were purified from human peripheral blood monocyte cells. As shown in Figures  1b and c , Ad-k35GFP-transduced B cells expressed significantly higher levels of GFP than AdGFP-transduced B cells. These data indicated that the modified adenoviral vector, Ad-k35, could be used to enhance gene delivery to human B cells.
Enhanced antigen gene delivery with the Ad-k35 vector in both human and murine B cells For the establishment of B-cell-based vaccines, both adenoviral vector transduction into B cells and proper expression of the transduced antigen is crucial to the generation of antigen-specific immune responses. To test this, we introduced a truncated form of the breast cancer antigen, Her2/neu (HM) into Ad-k35 vectors (Adk35HM). An HM-encoding adenovirus serotype 5 (AdHM) was used as a control. We transduced these HM-encoding adenoviral vectors to human B cells and evaluated HM mRNA expression by real-time PCR at various time points after the adenoviral vector infections. B/Ad-k35HM rapid induced a 60-fold increase in mRNA expression over that of B/AdHM at 12 h; however, the expression level decreased at 18 h in the B/Ad-k35HM-transduced cells while those transduced with B/AdHM maintained a constant mRNA expression level (Figure 1e ). Although the HM mRNA expression increased transiently following Ad-k35HM transduction, we observed that the HM protein level gradually increased until 48 h after adenoviral vector transduction. Moreover, Ad-k35HM-transduced B cells showed significantly higher levels of HM protein expression than AdHM-transduced B cells (Supplementary Figure 1) . Furthermore, we found higher expression levels of CD86, CD80 and major histocompatibility complex (MHC) class II on the surfaces of B/Ad-k35HM-transduced human B cells than on B/ AdHM-transduced cells. The CD40 expression on the cells of the B/ Ad-k35HM group was also higher than that of the B/AdHM group, although it was indistinguishable from that of the B-cell-only group (Figure 1d and Supplementary Figure 2a) . These data indicated that the substitution of the Ad5 fiber knob by the Ad35 fiber knob enhanced adenoviral gene delivery and more effectively activated the B cells.
To test these B-cell-based vaccines in mice, we examined whether Ad-k35HM could efficiently transfer adenoviral genes to murine B cells. The trend of HM mRNA expression in murine B cells was similar to that of human B cells. Specifically, a timedependent increase was observed until 12 h, which decreased by 18 h, however, gene expression was greatly enhanced by Adk35HM, such that 30-fold and 240-fold increases were observed at 6 h and 12 h, respectively, compared with the AdHMtransfected cells (Figure 2c ). These enhanced adenoviral gene transfer of Ad-k35HM led to significantly higher HM protein expression on murine B cells compared with AdHM (Figures 2a  and c) . At 18 h, the CD86 expression on murine B cells transduced with Ad-k35HM was transiently higher than that of B cells transduced with AdHM (Figure 2b ). In addition, CD80 and CD40 expressions were slightly increased by Ad-k35 adenoviral vector transduction to B cells than that of AdHM-transduced cells while MHC class II molecule expression was not changed (Supplementary Figure 2b) . To test the in vitro toxicities of the adenoviral vectors, the percentages of ANX5 À /PI À live B cells were analyzed at 24 h after the B cells had been transduced with the indicated adenoviral vectors. Neither of the adenoviral vector transductions influenced B-cell viability (Figure 2d ). Collectively, these data indicate that Ad-k35HM enhances antigen gene delivery to and CD86, CD80 and CD40 expression on murine B cells without affecting cell viability. (Figure 3c ). These data suggest that KBC009-loaded B cells can directly activate NKT cells in vivo; NKT cells can subsequently stimulate B cells and activate them to become immunogenic APCs that can induce overall immune responses, as previously described. 6, 7, 10 Next, we investigated AdHM or Ad-k35HM-transduced B-cellbased vaccine-induced cytotoxic T-cell responses in mice. To evaluate antigen-specific cytotoxic T lymphocyte (CTL) activity, carboxyfluorescein succinimidyl ester (CFSE)-labeled, CTL epitope peptide-loaded syngeneic splenocytes were transferred intravenously into B-cell-based vaccine-immunized mice. Almost all of the CTL peptide-loaded target cells were lysed in mice from the B/ Ad-k35HM/KBC009 group. In addition, the B/Ad-k35HM group showed marked levels of specific target lysis, although these were relatively lower than in the B/Ad-k35HM/KBC009 group. However, no significant CTL responses were observed in the B/AdHM/ KBC009-immunized mice ( Figure 3d ). These data suggest that immunization with B/Ad-k35HM/KBC009 could effectively induce strong antigen-specific CTL responses.
Ad-k35HM-transduced B-cell-based vaccination induced humoral immune responses Antigen-specific antibody responses are a crucial part of an effective antitumor immune response. To evaluate the antigenspecific antibody production, we measured the Her2/neuspecific serum antibody titer in the indicated B-cell-based vaccine-immunized mice by analyzing the binding of diluted sera to CT26-hHer2 tumor cells. In B/Ad-k35HM or B/Adk35HM/KBC009-immunized mice, the Her2/neu-specific antibody titers were significantly elevated until 8 weeks after immunization (Figures 4a and b) . Relatively higher specific antibody titers were observed in the B/Ad-k35HM/KBC009 group compared with the B/Ad-k35HM group at 5 weeks after immunization. In contrast, no significant antigen-specific antibody production was observed in the B/AdHM and B/AdHM/ KBC009 groups.
Next, we examined whether these Her2/neu-specific antibodies could exert antibody-dependent cell-mediated cytotoxicity (ADCC) activity against Her2/neu-expressing Sk-Br-3 human tumor cells. Serum antibodies from the B/Ad-k35HM/KBC009 group more efficiently killed Sk-Br-3 than did those from the B/Ad-k35HM group at weeks 3 and 5 ( Figure 4c ). Serum antibodies from the B/ AdHM and B/AdHM/KBC009 groups did not exhibit significant ADCC activities. Collectively, immunization with B/Ad-k35HM/ KBC009 effectively generated a strong antigen-specific humoral immune response.
Ad-k35HM-transduced B-cell-based vaccination inhibited the growth of established tumors Although B/Ad-k35HM/KBC009 immunization efficiently generated both cellular and humoral immune responses, it remained unclear whether these specific immune responses could effectively inhibit the growth of established tumors in vivo. To ascertain the antitumor therapeutic effects of B/Ad-k35HM/KBC009, we subcutaneously implanted CT26-hHer2 cells into naive mice, which were then treated with B-cell-based vaccines 5 days later (Figure 5a) . B/Ad-k35/KBC009 vaccination more effectively inhibited tumor growth than did vaccination with either B/AdHM/ KBC009 or B/Ad-k35HM (Figure 5b ).
These data indicate that enhanced Ag transduction, facilitated by Ad-k35HM and NKT ligand-loading of B cells, was crucial to the B-cell-based vaccine-mediated generation of antitumor immunity. Overall, these data suggest that B/Ad-k35HM/KBC009 might be an ideal to be therapeutic vaccine regimen for Her2/neu-expressing solid cancers. 7 of an equal mixture of 20 mM CFSE-labeled, 1.5 mg ml -1 hp63-loaded syngeneic splenocytes and 2.5 mM CFSE-labeled splenocytes was injected into the immunized mice. The hp63-specific lysis was analyzed by flow cytometry at 18-h post-target injection. All data are representative of two independent experiments (*Po0.05, **Po0.01, ***Po0.001).
Induction of a human HLA-A2 epitope-restricted CD8 þ T-cell immune response by an Ad-k35HM-transduced B-cell-based vaccine Next, we tested whether the Ad-k35HM-transduced NKT ligandloaded B-cell-based vaccines could also induce human MHC molecule-restricted CD8
þ T-cell immune responses. To ascertain this, we used transgenic mice that expressed a hybrid class I MHC gene (AAD mice) that encoded the epitope peptide-binding alpha-1 and alpha-2 domains of the human HLA-A2.1 gene and the transmembrane and cytoplasmic alpha-3 domains of the murine H-2D d gene. These mice have been widely used for evaluations of human HLA-A0201-restricted cytotoxic T-cell responses. [33] [34] [35] The AAD mice were immunized with Ad-k35HM-transduced B-cellbased vaccines and after 9 days, the splenocytes were re-stimulated ex vivo with either two Her2/neu-specific, and HLA-A2-restricted nine-mer peptides (a mixture of hp363 and hp435) or TC1-A2/HM murine tumor cells, which express both HLA-A2 and Her2/neu. As shown in Figures 6a and b , re-stimulation with either the peptides or TC1-A2/HM significantly increased the numbers of IFNg þ spots from B/Ad-k35HM/KBC009 group splenocytes. B/Ad-k35HM group splenocytes also produce IFNg but at relatively lower levels than the B/Ad-k35HM/KBC009 group cells. A similar result was observed when the IFNg concentrations were measured in the TC1-A2/HM restimulated culture supernatants (Figure 6c ). These data imply that B/Ad-k35HM/KBC009 effectively elicited HLA-A2-restricted antigenspecific CTL responses.
DISCUSSION
In this report, we describe an advanced B-cell-based anticancer therapeutic vaccine that exhibited enhanced cancer immunotherapeutic effects. B/Ad-k35HM/KBC009, a soluble NKT ligand KBC009-loaded, Ad-k35HM-transduced B-cell-based vaccine induced a strong and broad spectrum of immune responses that encompassed both adaptive and innate immunity and ultimately inhibited the growth of established tumors in vivo.
The proper generation of strong immune responses against tumor antigen is required for successful clinical tumor immunotherapy outcomes. Traditional vaccination strategies that are administered against infectious diseases, such as co-injections of antigen or antigen-encoding DNA with an adjuvant, have been adapted in early cancer therapeutic vaccine development. These methods are simple and cost effective, but unfortunately have been ineffective as solid cancer treatments because they could not provide the necessary in situ APCs stimulation that was required for the priming of antigen-specific immune responses. 1 Recently, tumor antigen-expressing, ex vivo-differentiated, mature autologous dendrite cell-based vaccines have been developed and have been shown to effectively induce tumor antigen-specific immunity. However, expensive and labor-intensive ex vivo manipulations are required to generate dendritic cell-based vaccines, although these promise powerful therapeutic antitumor immunity.
3-5 Therefore, we, along with others, suggested B cells as an alternative source of APC-based vaccines 51 Cr release assay. The 1/750 diluted week 3 sera and 1/3000 diluted week 5 sera from indicated B-cell-based vaccine-immunized mice were used (*Po0.05, **Po0.01, ***Po0.001). All data were representative of two independent experiments. that were easily obtainable from human blood and did not require ex vivo maturation for cellular vaccine preparation. 6, 8, 9 Previously, we showed that NKT ligand-loaded on and antigen introduced by epitope peptide loading or adenoviral vector transduction to B cells could generate a broad spectrum of antigen-specific immune responses. 6, 10 Strategies of tumor antigen delivery to B cells are another important issue in the clinical development of B-cell-based vaccines. Although exogenous epitope peptide loading is simple and effective, this strategy is limited because of the various patient MHC haplotypes. 4 To overcome this problem, whole antigen introduction into B cells by transduction with an antigen gene-encoding serotype-5 based replicationincompetent adenoviral vector was suggested. 7 The adenovirally transduced tumor antigen could be processed within B cells and subsequently presented on the B-cell surface by most MHC molecules. However, adenovirus-5-based adenoviral vectors have low antigen transduction efficiency because of the lack of coxsackievirus and adenovirus receptor molecules expression on APCs such as B cells. To overcome this limitation, we previously reported the combined use of an adenoviral vector and an adapter molecule, CFm40L; this combination demonstrated enhanced transduction efficacy and subsequent antitumor immune responses from B-cell-based vaccines. 19 However, it remains unknown whether this combination induces undesirable immune responses against the chimeric protein, CFm40L and consequent toxicities. Therefore, there has been a demand for alternative adenoviral vectors to allow more efficient delivery of tumor antigen genes to APCs. Ad35 was recently suggested because it can easily deliver genes through CD46 molecules expressed on most human leukocytes. 24, 25 Repeated vaccination with Ad35 induced stronger memory CD8 T-cell responses than vaccination with Ad5, indicating that Ad35 could be a useful alternative adenoviral vector, which could replace Ad5. 36 Also, there are various challenges in the construction of modified adenoviral vectors for transduction enhancement or specific in vivo targeting. In this study, we designed a replicateincompetent Ad5-based modified adenoviral vector containing a substituted Ad35 fiber knob (Ad-k35) to take advantage of Ad35's infectivity. This approach enabled us to anticipate the enhanced transduction efficiency by the Ad-k35 adenoviral vector. As expected, compared with AdHM, the tumor antigen-introduced Ad-k35HM (Ad-k35/HM) showed superior infectivity in B cells (Figures 1d and 2a) and subsequently enhanced the antigen expression on B cells, eliciting stronger cellular (Figures 3c and 6 ) and humoral immune responses (Figure 4 ) and enhancing antitumor activity ( Figure 5 ). Collectively, these data indicate that the Ad-k35 vector is appropriate for B-cell-based cancer therapeutic vaccine development.
In this study, we investigated the development of advanced B-cell-based vaccine with an Ad-k35 adenoviral vector, which enhances antigen delivery to B cells. We hypothesized that antigen transfer enhancement with an Ad-k35 adenoviral vector might elicit enhanced overall antigen-specific immune responses and subsequently maximize the cancer therapeutic effects of B-cell-based vaccines. To ascertain this, we introduced a truncated form of well-known tumor antigen Her2/neu to Ad-k35 adenoviral vector (Ad-k35/HM) to enhance the adenoviral antigen transfer. As expected, the Ad-k35 adenoviral vector greatly increased the antigen transduction efficiency in human B cells (Figure 1) . 31, 38 Moreover, enhanced antigen transfer to human B cells subsequently elevated expression of several co-stimulatory molecules (Figures 1d and f, Supplementary Figure 1a) suggesting that transduced adenoviral vector might act as an adjuvant. 11 However, it is unclear if the increased expression was due to the substituted Ad35 fiber knob or to the enhanced adenoviral vector delivery to B cells. As the intracellular signaling events triggered by CD46 ligation are still unknown, the changes in the intracellular events induced by ligation of the k35 fiber knob-CD46 on human B cells need to be investigated in future studies.
Despite the rare expression of CD46 on murine leukocytes, 37 Ad-k35HM also improved the transduction efficiency in murine B cells (Figure 2a) , which means that its underlying mechanism is independent on CD46. 31, 38 Recently, several studies reported that the Ad35 could enter host cells by both CD46-dependent and CD46-independent mechanisms; 31,38 thus further studies might be needed to determine the mechanisms of CD46-independent entrance.
As well as enhancing antigen transduction into B cells, the copresentation of NKT ligands and processed antigen on same B cells is crucial to the generation of antigen-specific immune responses of B-cell-based vaccines. 6 Although a-GC is a wellknown NKT ligand, its poor solubility needs to be improved upon for the clinical development of NKT ligand-loaded B-cell-based vaccines. Therefore, we used KBC009, a water-soluble derivative of a-GC. 32 The KBC009-loaded B cells effectively activated NKT cells in vivo, regardless of adenoviral vector transductions (Figures 3a  and b, Supplementary Figure 3) . Moreover, activated NKT cells can subsequently stimulate B cells and activate them to become immunogenic APCs that can induce overall immune responses (Figure 3c) . 6, 7, 10 These data implicate KBC009-loaded, Ad-k35HM-transduced B-cell-based vaccines could promote overall in vivo antigen-specific immunity, which includes NKT cell activation.
As expected, B/Ad-k35HM/KBC009 immunization effectively generated strong Her2/neu-specific immune responses, including cytotoxic T-cell-mediated cytotoxicity (Figure 3c) . Interestingly, B/Ad-k35HM immunization induced both significant antigenspecific target lysis and antibody production in the absence of NKT activation. These data suggest that the modified adenoviral vector Ad-k35 could act as a strong adjuvant to enhance the APC functions of B cells. Moreover, vaccination with B/Ad-k35HM/ KBC009 also elicited enhanced Her2/neu-specific antibody production and ADCC (Figure 4) . These results suggest that the enhanced humoral immune responses induced by B/Ad-k35HM/ KBC009 vaccination may be related to the differentiation of follicular helper T (T FH ) cells. Recently, T FH cells have been demonstrated as a helper T-cell subset controlling humoral immunity. 39, 40 The enhanced humoral immunity induced by B-cell vaccination may be related to the differentiation of T FH cells and germinal center formation in the spleen, where transferred B-cell-based vaccines mainly reside. 10 However, further studies are needed to investigate the underlying in vivo mechanisms responsible for this result.
Furthermore, either B/Ad-k35HM or B/Ad-k35HM/KBC009 vaccination of AAD mice effectively induced HLA-A2 antigen-restricted CD8
þ T-cell immune responses ( Figure 6 ) implying that these B-cell-based vaccines could also be effective in human immune system.
The antigen-specific immune responses induced by the Adk35HM-transduced B-cell-based vaccines also effectively inhibited the growth of established tumors in a mouse model, and the additional NKT cell activation further enhanced the antitumor effects of the B-cell-based vaccines ( Figure 5) . Surprisingly, although B/AdHM/KBC009 vaccination elicited poor antigenspecific immune responses, it moderately inhibited tumor growth, implicating the importance of activated NKT cell-mediated antitumor effects and possibly NK cell trans-activation by activated NKT cells. 7 Taken together, this study proposes B/Ad-k35HM/KBC009 as a novel and advanced B-cell-based therapeutic vaccine regimen for the treatment of Her2/neu-expressing solid cancers. In addition, NKT ligand-loaded, Ad-k35 adenoviral vector tumor antigentransduced B cells could be useful in the development of therapeutic cell-based vaccines for various cancers.
MATERIALS AND METHODS Mice
BALB/c mice were purchased from the Charles River Laboratories (Seoul, Korea). Chimeric HLA-A2 Tg mice (B6.Cg(CB)-Tg(HLA-A/H2-D)2Enge/Jat), (AAD mice) were purchased from the Jackson Laboratories (Bar Harbor, ME, USA). All mice housed in specific pathogen-free conditions in the Animal Center for Pharmaceutical Research at Seoul National University. The experiments were approved by the International Animal Care and Use Committee of Seoul National University.
Reagent and antibodies
Antibodies for flow cytometry were purchased from either Biolegend (San Diego, CA, USA) or BD Bioscience (San Jose, CA, USA). Anti-mouse B220-FITC, anti-mouse TCRb-FITC, anti-mouse IA/IE-FITC, anti-mouse CD40-PEcy7, anti-mouse CD80-PE, anti-mouse CD86-PE, anti-mouse CD69-APC, anti-human CD86-PE and anti-human CD40-PEcy7 were purchased from Biolegend. Anti-human CD20-FITC (2H7), anti-human HLA-DP/DQ/DR-FITC, anti-human CD80-PE, anti-human Her2/neu-APC, Annexin 5-APC and propidium iodine staining solution, recombinant CD1d dimer (Dimer X) were purchased from BD Bioscience. All microbeads for B-cell isolation (anti-mB220 and anti-huCD19) were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). Nine-mer CD8 þ T-cell epitope peptides of Her2/neu were purchased from AnyGen (Jeonnam, Korea). The following peptides were used: Her2/neu 63-71 (hp63, TYLPTNASL), Her2/neu 369-377 (hp369, KIFGSLAFL) and Her2/neu 435-443 (hp435, ILHNGAYSL).
Cell lines and culture
The human Her2/neu-expressing transfectoma cell line CT26-hHer2 was developed as previously described. 41 A Her2/neu-expressing SK-Br-3 human breast carcinoma cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). The TC1-A2/HM cell line was developed by transfecting pCK-HM into TC1-A2 cells that were kindly provided by Dr TC Wu (The Johns Hopkins University School of Medicine, Baltimore, MD, USA). 42 Tumor cells were cultured in Dulbecco's modified Eagle's medium medium that was supplemented with 1% penicillin/ streptomycin (Lonza, Walkersville, MD, USA) and 10% fetal bovine serum (GIBCO, Grand Island, NY, USA). Isolated human and murine B cells were cultured in RPMI 1640 medium that was supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, 10 mM HEPES, 1 mM sodium pyruvate, 0.1 mM non-essential amino acid and 0.05 mM b-mercaptoethanol.
Adenoviral vectors
All adenoviral vectors were constructed by Professor CO Yun (Hanyang University, Seoul, Korea). To construct the adenoviral vector that expressed the Her2/neu gene (HM) or the GFP reporter gene in the E1 region of adenovirus type 5, we first constructed a pCA14-E1 adenovirus shuttle vector (Microbix, Ontario, Canada) that expressed Her2/neu or GFP. The newly generated pCA14-E1-HM or pCA14-E1-GFP vector was co-transformed with an E1/E3-deleted replication-incompetent adenovirus derived from human adenovirus type 5 (E1; SB Verca, University of Fribourg, Fribourg, Switzerland) or an E1/E3-deleted replication-incompetent Ad 5/35 chimeric vector in which a portion of the Ad type 5 fiber was replaced by a portion of the Ad type 35 fiber (Ad-k35), 30 yielding the plasmids pdE1/HM, pdE1/GFP, pdE1-k35/HM and pdE1-k35/GFP. These recombinant plasmids were transfected into human embryonic kidney 293 cells to generate AdHM, AdGFP, Ad-k35HM and Ad-k35GFP. All viruses were obtained as previously described. 43 B-cell isolation and B-cell-based vaccine preparation Murine B cells were isolated from total splenocyte using anti-mB220 microbeads. The preparation of human peripheral blood monocyte cells was previously described. 44 B cells from human peripheral blood monocyte cells were isolated by anti-huCD19 microbead, according to the manufacturer's instructions. Isolated B cells were transduced with the indicated multiplicity of infection of adenoviral vectors in a 90 min, 2800 r.p.m. centrifugation step at room temperature, and the cells were subsequently incubated for an additional 18 h. In some experiments, KBC009 was loaded into the prepared B cells for NKT activation, based on our previous studies. 6, 10, 45 Quantitative real-time PCR Total RNA was isolated by an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and then reverse-transcribed using amfiRivert Platinum (GenDEPOT, Baker, TX, USA). Quantitative real-time PCR was performed on a LightCycler optical system (Roche, Basel, Switzerland) and SYBR Premix Ex Taq (Takara, Otsu, Japan). Expression levels of the target genes were calculated relative to Hprt expression. The following primers were used: murine Hprt sense 
In vivo NKT activation and in vivo transferred B-cell analysis
The a-GC derivative KBC009 was used as an NKT ligand. 32 Purified B cells from murine splenocytes were transduced with 100 multiplicity of infection of the indicated HM-encoding adenoviral vectors and subsequently loaded with 1 mg ml -1 of KBC009 or vehicle. Untreated B cells were used as controls. After an overnight incubation, 2 Â 10 6 manipulated B cells were intravenously injected into mice. Four hours later, the mice were killed and CD69 expression on splenic NKT cells were analyzed by flow cytometry on a FACS Calibur (BD Bioscience). In addition, after a 4-h treatment with the manipulated B cells, the serum levels of IFNg and IL-4 were determined by enzyme-linked immunosorbent assay (BD Bioscience) according to the manufacturer's instructions. For analysis of activation markers on transferred B cells, 2 Â 10 6 cells of 10 mM of CFSE-labeled B or B/KBC009 were injected to mice. Twenty-four hours later, CFSE þ B cells in murine splenocytes were analyzed by flow cytometry.
Evaluation of cytotoxic T-cell responses
Cytotoxic T-cell responses were evaluated by an in vivo CTL assay as previously described. 7 Briefly, the target cells were prepared from syngeneic lymphocytes loaded with 1 mg ml -1 of the hp63 epitope peptide and subsequently labeled with 20 mM CFSE. Syngeneic lymphocytes labeled with 2.5 mM CFSE were used as an internal control. Equal amounts of target cells and internal control cells were injected intravenously into B-cell-based vaccine-treated mice. The mice were killed at 18-h post-target cell injection, and peptide-specific target lysis was analyzed by flow cytometry. The specific lysis was calculated as follows: r (ratio) ¼ (% CFSE low /% CFSE high ), % lysis ¼ [1-(r unprimed /r primed )] Â 100.
Evaluation of humoral immune response
Humoral immune responses were assessed by an ADCC assay and specific antibody titers as previously described. 10 For ADCC, diluted sera from immunized mice and syngeneic splenocytes that contained various effector cells were co-incubated with 51 Cr-labeled Her2/neu-expressing Sk-Br-3 target cells. After a 4-h co-incubation, 51 Cr radioactivity in the supernatants was measured with a Wallac 1470 Wizard automatic g-counter (Perkinelmer, Waltham, MA, USA). Specific lysis (%) was calculated as follows: % ¼ [(experimental release-spontaneous release)/ (maximum release-spontaneous release)] Â 100. Specific Her2/neu antibody titers were determined by the binding of diluted sera from immunized mice to CT26-hHer2 cells; binding was detected by flow cytometry, using a FITC-labeled goat anti-mouse immunoglobulin G as a secondary antibody (Sigma Aldrich Korea, Seoul, Korea).
Therapeutic tumor model
For the therapeutic tumor model, 2 Â 10 5 CT26-hHer2 cells were subcutaneously injected into left flanks of naive mice on day 0. The indicated B-cell-based vaccine were administrated on day 5. Tumor growth was measured with calipers every 2 days.
Statistics
The data are shown as the means ± s.e.m., and statistical significance was analyzed with Graph Pad Prism software (La Jolla, CA, USA). A two-tailed Student's t-test was used to compare differences between two groups. Both one-way and two-way analysis of variances were used to compare difference among multiple groups. P-values o0.05 were considered significant at a 95% confidence interval.
